OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias	30
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib	27
Venetoclax-containing regimens in acute myeloid leukemia	24
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies	23
Bortezomib in autoimmune hemolytic anemia and beyond	22
Current evidence and the emerging role of eltrombopag in severe aplastic anemia	21
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review	19
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria	19
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy	17
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)	16
Clinical features ofDDX41mutation-related diseases: a systematic review with individual patient data	15
Primary central nervous system lymphoma in the United States, 1975–2017	15
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia	14
International consensus recommendations on the management of people with haemophilia B	14
Current and emerging treatment options in primary mediastinal B-cell lymphoma	13
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor	13
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia	12
The potential of pirtobrutinib in multiple B-cell malignancies	12
Current state of CAR-T therapy for T-cell malignancies	12
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective	12
Advances in therapeutic options for newly diagnosed, high-risk AML patients	11
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	11
MYD88^L265Pand CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy	11
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma	11
The role of carfilzomib in relapsed/refractory multiple myeloma	11

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications	11
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study	10
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers	10
The role of tazemetostat in relapsed/refractory follicular lymphoma	10
Mantle cell lymphoma management trends and novel agents: where are we going?	10
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma	10
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy	9
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)	9
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data	9
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma	9
Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation	8
Emicizumab in acquired haemophilia A: about two clinical cases and literature review	8
Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol	8
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma	8
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma	8
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia	8
Acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration	8
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)	8
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10⁹/L to <100 × 10⁹/L) at baseline: the final analysis of EXPAND	7
The use of tafasitamab in diffuse large B-cell lymphoma	7
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-int	7
Update on the role of copanlisib in hematologic malignancies	7
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)	6
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations	6
Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens	6
Treosulfan-based conditioning for inborn errors of immunity	6
Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist	6
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation	6
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study	6
Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors	6
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia	6
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis	5
Prophylactic management of patients with von Willebrand disease	5
Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation	5
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis	5
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia	5
Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide	5
Outpatient allogeneic hematopoietic stem-cell transplantation: a review	5
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study	5
Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation	5
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib	5
Zanubrutinib in lymphoproliferative disorders: a comprehensive review	5
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report	5
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study	5
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma	5
Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies	5
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study	5
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma	4
The role of acalabrutinib in adults with chronic lymphocytic leukemia	4
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?	4

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia	4
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma	4
Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report	4
Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma	4
Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report	4
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?	4
Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe ap	4
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond	4
Case series: MRD negativity assessment using ¹¹C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma	4
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain	4
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States	4
Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome	4
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry	3
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	3
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report	3
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality	3
Considerations for shared decision management in previously untreated patients with hemophilia A or B	3
Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study	3
Iron overload status in patients with non-transfusion-dependent thalassemia in China	3
Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome	3
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges	3
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations	3
Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia	3
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review	3
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente	3
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments	3
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma	3
How to translate and implement the current science of gene therapy into haemophilia care?	3